Cargando…
E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function
BACKGROUND: The E-cadherin gene (CDH1) is frequently mutated in diffuse gastric cancer and lobular breast cancer, and germline mutations predispose to the cancer syndrome Hereditary Diffuse Gastric Cancer. We are taking a synthetic lethal approach to identify druggable vulnerabilities in CDH1-mutant...
Autores principales: | Godwin, Tanis D., Kelly, S. Thomas, Brew, Tom P., Bougen-Zhukov, Nicola M., Single, Andrew B., Chen, Augustine, Stylianou, Cassie E., Harris, Lawrence D., Currie, Sophie K., Telford, Bryony J., Beetham, Henry G., Evans, Gary B., Black, Michael A., Guilford, Parry J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394693/ https://www.ncbi.nlm.nih.gov/pubmed/30066183 http://dx.doi.org/10.1007/s10120-018-0859-1 |
Ejemplares similares
-
Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells
por: Bougen-Zhukov, Nicola, et al.
Publicado: (2019) -
A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells
por: Beetham, Henry, et al.
Publicado: (2019) -
Loss of E-Cadherin Leads to Druggable Vulnerabilities in Sphingolipid Metabolism and Vesicle Trafficking
por: Brew, Tom, et al.
Publicado: (2021) -
E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors
por: Decourtye-Espiard, Lyvianne, et al.
Publicado: (2021) -
E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib
por: Bougen-Zhukov, Nicola, et al.
Publicado: (2022)